Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biomarker studies and other difficult inferential problems: statistical caveats.

Donald A Berry1

  • 1The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA. dberry@mdanderson.org

Seminars in Oncology
|May 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results.

Nature cancer·2026
Same author

Statistical innovations in clinical trial design with a focus on drug combinations, factorials, and other multiple therapy issues.

The journal of prevention of Alzheimer's disease·2025
Same author

Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research.

Journal of clinical medicine·2025
Same author

Annual Versus Biennial Mammographic Screening.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Biomarker studies often yield complex results and numerous false positives. This study proposes reducing multiple biomarkers to a single dimension to confirm prognostic value, using estrogen-receptor status as an example in breast cancer treatment.

Area of Science:

  • Oncology
  • Biostatistics
  • Genomics

Background:

  • Biomarker studies are crucial for understanding cancer heterogeneity and treatment outcomes.
  • The proliferation of potential biomarkers leads to significant inferential challenges, including a high rate of false-positive findings.
  • Statistical complexities arise from analyzing numerous biomarkers simultaneously.

Purpose of the Study:

  • To address the complexity and high false-positive rates in biomarker research.
  • To propose a method for reducing multiple biomarkers into a single dimension for analysis.
  • To statistically evaluate the predictive value of this single-dimensional approach, exemplified by estrogen-receptor status in breast cancer.

Main Methods:

  • Dimensionality reduction techniques applied to multiple biomarker data.

Related Experiment Videos

  • Statistical modeling to assess prognostic and predictive values.
  • Analysis of estrogen-receptor status in relation to chemotherapy benefits for node-positive breast cancer.

    • Main Results:

    • A strategy for reducing biomarker dimensionality can mitigate some statistical challenges.
    • Estrogen-receptor status demonstrates predictive value for chemotherapy benefits in node-positive breast cancer patients.
    • The proposed approach helps in confirming the clinical utility of biomarkers.

    Conclusions:

    • Reducing biomarker complexity to a single dimension is a valuable strategy in oncology research.
    • This approach can help reduce false-positive conclusions and improve the reliability of biomarker findings.
    • Estrogen-receptor status serves as a key example of a predictive biomarker in breast cancer treatment decisions.